文献速递肥胖与代谢综合征糖尿病

胰高血糖素样肽-1/胰高血糖素受体双重激动用于肥胖治疗

GLP-1/glucagon receptor co-agonism for treatment of obesity.
PubMed 文献 · Diabetologia · 2017-07-21

肥胖与2型糖尿病构成全球重大医疗经济负担,现有药物减重效果有限且不良反应明显,减重手术是当前唯一能大幅改善体重的疗法。本综述聚焦作用于胰高血糖素受体和胰高血糖素样肽-1受体的双重激动剂的发现与转化研究,此类单分子多肽已推进至临床评估,并启发了在单一分子内实现多重药理作用的多种相关策略。

要点

  • 肥胖和2型糖尿病是可预防的早逝原因之一,亟需新型安全有效的抗肥胖药物。
  • 现有药物减重效果有限且不良反应明显,减重手术是当前唯一能大幅改善体重的疗法。
  • 作用于胰高血糖素和胰高血糖素样肽-1受体的双重激动剂已推进至临床评估。

核心结论

  • 作用于胰高血糖素和胰高血糖素样肽-1受体的双重激动剂已推进至临床评估,并启发了在单一分子内实现多重药理作用的多种相关策略。

研究设计与样本

  • 本综述主要聚焦于作用于胰高血糖素受体和胰高血糖素样肽-1受体的双重激动剂的发现与转化相关性。

主要发现

  • 新型单分子多功能多肽已成为增强代谢效能和恢复正常体重的最有前景的医学方法之一。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sánchez-Garrido MA, Brandt SJ, Clemmensen C, et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017. PMID: 28733905. doi:10.1007/s00125-017-4354-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。